LUCIUS 卢修斯 索拉非尼 Sorafenib肝细胞癌 晚期肾细胞癌 甲状腺癌

索拉非尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Sorafenib

老挝国家食药监局批准上市
老挝国家药检所检测认证
肝细胞癌

Composition:
Each film-coated tablet contains Sorafenib

晚期肾细胞癌

idie.re ig equrvalent to

LUCIUS
PHARMACEUTICALS

Lucisora is a kinase inhibitor indicated for th
treatmentof

LuciSora

甲状腺癌

Unresectable hepatocellular carcinom
. Advanced renal cell carcinoma.
differentiated thuroid carcinoma refractoryt
*400 mg (2 tablets) orally twice daily without

Sorafenib Tablets

Tood.
Tranksont interr
nterruption and or dose reduction

may be needed to manage adverse reactions.

200mg

FDA批准

Storage: in a dry place and store at 20C to 25C.
Waraing:
Keep medicine out of reach of Children. Do nol
administer LuciSora during Preenancy and

120 Tablets

Lactafion.

PLEASE SEE PACKAGE INSERT
Cmlidren. Do nol
Manufactured and Marketed by:

LUCIUS

PHARMACEUTICALS

权威认证

Thongmang village, Xaythany district.
Vientiane Capital, Laos
www.lucius.la
Warnins: To be soldi
of remall on prescrplion
byleolans only, and as directed

Rx Only

口碑质量

适应症:

1、不可切除的肝细胞癌。
2、晚期肾细胞癌。
3、对放射性碘治疗有抵抗力的局部复发或转移性、进行
性、分化型甲状腺癌。
推荐剂量:
1、每日两次,每次400mg(2片),不与食物同服。
2、可能需要中断治疗和/或减少剂量以控制不良反应。